Literature DB >> 7871759

Dengue fever virus and Japanese encephalitis virus synthetic peptides, with motifs to fit HLA class I haplotypes prevalent in human populations in endemic regions, can be used for application to skin Langerhans cells to prime antiviral CD8+ cytotoxic T cells (CTLs)--a novel approach to the protection of humans.

Y Becker1.   

Abstract

Flaviviruses were reported to induce CD8+ cytotoxic T cells in infected individuals, indicating that nonapeptides, proteolytic cleavage products of the viral precursor protein, enter the endoplasmic reticulum in infected cells and interact with HLA class I molecules. The assembled HLA class I molecules are transported to the plasma membrane and prime CD8+ T cells. Current knowledge of the interaction of viral peptides with HLA molecules is reviewed. Based on this review, an idea is presented to use synthetic flavivirus peptides with an amino acid motif to fit with the HLA class I peptide binding group of HLA haplotypes prevalent in a given population in an endemic area. These synthetic viral peptides may be introduced into the human skin using a lotion containing the peptides ("Peplotion") together with substances capable of enhancing the penetration of these peptides into the skin to reach Langerhans cells. The peptide-treated Langerhans cells, professional antigen-presenting cells, may bind the synthetic viral peptides by their HLA class I peptide-binding grooves. Antigens carrying Langerhans cells are able to migrate and induce the cellular immune response in the lymph nodes. This approach to the priming of antiviral CD8+ cytotoxic T cells may provide cellular immune protection from flavivirus infection without inducing the humoral immune response, which can lead to the shock syndrome in Dengue fever patients. To be able to develop anti-Dengue virus synthetic peptides for populations with different HLA class I haplotypes, it is necessary to develop computational studies to design HLA class I Dengue virus synthetic peptides with motifs to fit the HLA haplotypes of the population living in an endemic region for Dengue fever. Experiments to study Dengue virus and Japanese encephalitis peptides vaccines and their effectiveness in protection against Dengue fever and Japanese encephalitis are needed. The development of human antiviral vaccines for application of viral peptides in a lotion to human skin ("Peplotion") may be useful and affordable for populations of developing countries.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7871759     DOI: 10.1007/bf01703433

Source DB:  PubMed          Journal:  Virus Genes        ISSN: 0920-8569            Impact factor:   2.332


  74 in total

Review 1.  Antigen uptake and presentation by dendritic leukocytes.

Authors:  J M Austyn
Journal:  Semin Immunol       Date:  1992-08       Impact factor: 11.130

2.  Different length peptides bind to HLA-Aw68 similarly at their ends but bulge out in the middle.

Authors:  H C Guo; T S Jardetzky; T P Garrett; W S Lane; J L Strominger; D C Wiley
Journal:  Nature       Date:  1992-11-26       Impact factor: 49.962

3.  Fusion activity of flaviviruses: comparison of mature and immature (prM-containing) tick-borne encephalitis virions.

Authors:  F Guirakhoo; F X Heinz; C W Mandl; H Holzmann; C Kunz
Journal:  J Gen Virol       Date:  1991-06       Impact factor: 3.891

4.  Immunological enhancement of dengue virus replication.

Authors:  S B Halstead; J S Chow; N J Marchette
Journal:  Nat New Biol       Date:  1973-05-02

5.  Constitutive endocytosis of HLA class I antigens requires a specific portion of the intracytoplasmic tail that shares structural features with other endocytosed molecules.

Authors:  M A Vega; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

6.  A hypothetical model of the foreign antigen binding site of class II histocompatibility molecules.

Authors:  J H Brown; T Jardetzky; M A Saper; B Samraoui; P J Bjorkman; D C Wiley
Journal:  Nature       Date:  1988-04-28       Impact factor: 49.962

7.  Cell biology. Bridging the gap.

Authors:  G Warren
Journal:  Nature       Date:  1993-03-25       Impact factor: 49.962

8.  Human cytotoxic T cells stimulated by antigen on dendritic cells recognize the N, SH, F, M, 22K, and 1b proteins of respiratory syncytial virus.

Authors:  A H Cherrie; K Anderson; G W Wertz; P J Openshaw
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

9.  SNAP receptors implicated in vesicle targeting and fusion.

Authors:  T Söllner; S W Whiteheart; M Brunner; H Erdjument-Bromage; S Geromanos; P Tempst; J E Rothman
Journal:  Nature       Date:  1993-03-25       Impact factor: 49.962

Review 10.  Human HIV vaccine trials: does antibody-dependent enhancement pose a genuine risk?

Authors:  D S Burke
Journal:  Perspect Biol Med       Date:  1992       Impact factor: 1.416

View more
  5 in total

1.  Computer simulations to predict the availability of peptides with known HLA class I motifs generated by proteolysis of dengue fever virus (DFV) type 1 structural and nonstructural proteins in infected cells.

Authors:  Y Becker
Journal:  Virus Genes       Date:  1995       Impact factor: 2.332

2.  Variation in antigenicity and infectivity of derivatives of Borrelia burgdorferi, strain B31, maintained in the natural, zoonotic cycle compared with maintenance in culture.

Authors:  W T Golde; M C Dolan
Journal:  Infect Immun       Date:  1995-12       Impact factor: 3.441

Review 3.  Dengue and dengue hemorrhagic fever.

Authors:  D J Gubler
Journal:  Clin Microbiol Rev       Date:  1998-07       Impact factor: 26.132

Review 4.  Infectious diseases and immunity: special reference to major histocompatibility complex.

Authors:  N Singh; S Agrawal; A K Rastogi
Journal:  Emerg Infect Dis       Date:  1997 Jan-Mar       Impact factor: 6.883

Review 5.  The next generation of antimicrobial peptides (AMPs) as molecular therapeutic tools for the treatment of diseases with social and economic impacts.

Authors:  Nicolau B da Cunha; Nicole B Cobacho; Juliane F C Viana; Loiane A Lima; Kamila B O Sampaio; Stephan S M Dohms; Arthur C R Ferreira; César de la Fuente-Núñez; Fabrício F Costa; Octávio L Franco; Simoni C Dias
Journal:  Drug Discov Today       Date:  2016-11-23       Impact factor: 7.851

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.